Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus Nivolumab in Pediatric and Young Adult Relapsed/Refractory Lymphoma (RELATIVITY-069)
2023-503715-14-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of relatlimab and nivolumab in classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL), primary mediastinal large B-cell lymphoma (PMBCL) and 7 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities (DLTs), MTD/RP2D, and safety profile in Part A, Pharmacokinetics of relatlimab in Part A and 1 more. Started Aug 2023; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
classical Hodgkin lymphoma (cHL)non-Hodgkin lymphoma (NHL)primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)mediastinal gray zone lymphoma (GZL)
Beyond the preview
Go deeper on 2023-503715-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503715-14-00.